Capricor's response
Capricor said HOPE-2 and HOPE-3 both met their primary endpoints and that it stands behind the integrity of its data. Chief executive Linda Marbán said: "Deramiocel has been studied in two randomized, double-blind, placebo-controlled trials, HOPE-2 and HOPE-3, both of which met their primary endpoints. We stand behind the rigor of our clinical program and the integrity of our data, and we believe the data support approval."
The company reported cash, cash equivalents, restricted cash and marketable securities of about $198.5 million at September 30, 2026, which it says is enough to fund planned operations for at least 12 months. It is reviewing the letter and will share next steps after its evaluation, and will hold a conference call and webcast on Monday, November 23, at 8:30 a.m. ET.